9FQO
Crystal structure of C0083 Fab targeting the oxidized macrophage migration inhibitory factor (oxMIF)
Summary for 9FQO
| Entry DOI | 10.2210/pdb9fqo/pdb |
| Descriptor | C0083 Fab heavy chain, C0083 Fab light chain, 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, ... (4 entities in total) |
| Functional Keywords | fab, antibody fragment, mif, anti-oxmif, cancer treatment, immunotherapy, immune system |
| Biological source | Homo sapiens More |
| Total number of polymer chains | 2 |
| Total formula weight | 47569.97 |
| Authors | Rossmueller, G.,Mirkina, I.,Thiele, M.,Puchol Tarazona, A.A.,Rueker, F.,Kerschbaumer, R.J.,Schinagl, A. (deposition date: 2024-06-17, release date: 2025-01-01, Last modification date: 2025-01-22) |
| Primary citation | Rossmueller, G.,Mirkina, I.,Thiele, M.,Puchol Tarazona, A.,Rueker, F.,Kerschbaumer, R.J.,Schinagl, A. Integrating In Silico and In Vitro Tools for Optimized Antibody Development-Design of Therapeutic Anti-oxMIF Antibodies. Antibodies, 13:-, 2024 Cited by PubMed Abstract: Rigorous assessment of antibody developability is crucial for optimizing lead candidates before progressing to clinical studies. Recent advances in predictive tools for protein structures, surface properties, stability, and immunogenicity have streamlined the development of new biologics. However, accurate prediction of the impact of single amino acid substitutions on antibody structures remains challenging, due to the diversity of complementarity-determining regions (CDRs), particularly CDR3s. PubMed: 39727487DOI: 10.3390/antib13040104 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.7 Å) |
Structure validation
Download full validation report
